RORA and breast carcinoma: Treatment with the RORα antagonist (SR1001) enhanced tumorsphere formation efficiency in MDA-MB 231 and HMT-3522 T4-2 cells, whereas the RORα agonist (SR1078) depressed tumorsphere formation in breast cancer cells (Figs. 4F and S4, C and D).